Celldex Therapeutics Inc
(NAS:CLDX)
$
35.07
0.4 (1.15%)
Market Cap: 2.31 Bil
Enterprise Value: 1.46 Bil
PE Ratio: 0
PB Ratio: 2.76
GF Score: 62/100 - Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 TranscriptFeb 25, 2024
- Celldex Therapeutics Inc Conference Call & Webcast TranscriptNov 06, 2023
- Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Celldex Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria TranscriptFeb 26, 2023
- Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call TranscriptDec 06, 2022
- Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 TranscriptJun 30, 2022
- Q4 2021 Celldex Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$29.9 (-0.83%)Earnings
- Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 16, 2022
- Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call TranscriptJul 12, 2021
- Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update TranscriptMar 29, 2021
- Q2 2020 Celldex Therapeutics Inc Earnings Call TranscriptAug 06, 2020$11.71 (+1.39%)Earnings
- Celldex Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q2 2019 Celldex Therapeutics Inc Earnings Call TranscriptAug 07, 2019$2.16 (+3.85%)Earnings
- Q4 2018 Celldex Therapeutics Inc Earnings Call TranscriptMar 07, 2019$4.6 (-1.71%)Earnings
Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call Transcript
Dec 06, 2022 / 01:00PM GMT
Release Date Price:
$36.34
(-0.87%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)